Welcome to our dedicated page for RenovoRx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RenovoRx, Inc. filings document the regulatory record of a life-sciences company commercializing RenovoCath® and developing targeted oncology therapies through its TAMP™ platform. Periodic and current reports disclose operating results, commercialization updates, clinical-trial strategy, and business updates related to the company’s investigational IAG drug-device candidate.
The company’s SEC record includes 8-K filings for financial results, material agreements, equity financings, warrant instruments, and at-the-market offering arrangements. Proxy materials cover annual meeting matters, board governance, executive compensation, and shareholder voting items, while leadership-related filings document officer appointments, compensatory arrangements, and reporting responsibilities.
RenovoRx, Inc. (symbol: RNXT) is the issuer of record for a Form 4 filing submitted to the SEC. VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. (RNXT) reported that its Chief Financial Officer, Mark Voll, received a grant of 80,000 restricted stock units (RSUs)222,380 shares of common stock directly and 97,200 shares indirectly through the Voll Family Trust. No Rule 10b5-1 trading plan is reported for this award.
RenovoRx, Inc. (RNXT) reports that its common stock has regained compliance with Nasdaq’s Minimum Bid Price Requirement under Listing Rule 5550(a)(2). The company previously received notice of non-compliance on December 31, 2025, after its closing bid price remained below $1.00 per share for 30 consecutive business days.
Nasdaq informed RenovoRx on August 20, 2026 that, for the ten consecutive business days from August 6, 2026 through August 19, 2026, the closing bid price of its common stock was $1.00 per share or greater. As a result, RenovoRx is now back in compliance with the Nasdaq minimum bid price standard and Nasdaq considers the matter closed.
RenovoRx, Inc. reported strong early commercialization momentum for its RenovoCath device while remaining deeply loss-making. Q2 2026 revenue was $909,000, up from $422,000 a year earlier, with six‑month revenue of $1.47 million versus $619,000 in 2025, reflecting broader adoption across active cancer centers.
Despite higher revenue, the company recorded a Q2 2026 net loss of $2.91 million and a six‑month net loss of $6.43 million, driven mainly by $8.06 million in operating expenses as it builds out commercial and clinical capabilities. Operating cash outflows were $6.58 million for the first half, partially offset by a March 2026 private placement that raised $10.0 million gross, leaving cash and cash equivalents of $9.48 million at June 30, 2026.
Management states current liquidity is expected to fund operations for at least 12 months from the report date, into the second half of 2027, but acknowledges that longer‑term growth, continued RenovoCath commercialization, and the Phase III TIGeR‑PaC trial for its IAG drug‑device candidate will likely require additional capital. The company also highlights multiple Orphan Drug Designations and continued progress toward completing TIGeR‑PaC, with clinical and investigator‑initiated studies intended to broaden its TAMP targeted‑delivery platform.
RenovoRx, Inc. reported record Q2 2026 revenue of $909,000, up approximately 61% from Q1 2026 and 115% from Q2 2025, driven by accelerating commercial adoption of its FDA-cleared RenovoCath device. Gross profit was $766,000, yielding an approximately 84% gross margin.
Net loss for the quarter was $2.9 million, similar to the prior year, as the company increased selling, general and administrative spending to build commercial infrastructure. Cash and cash equivalents totaled $9.5 million as of June 30, 2026, which the company believes will fund operations into the second half of 2027.
RenovoRx raised its 2026 revenue guidance to $3.75–$4.25 million, implying approximately 241%–286% growth over 2025. The company ended the quarter with 21 active commercial cancer center customers and a total commercial funnel of 63 centers. Its Phase III TIGeR-PaC trial reached full enrollment, with trial completion expected in the first half of 2027 and topline data in the second half of 2027.
RenovoRx, Inc. reported record second quarter 2026 results, with revenue of $909,000, up approximately 61% from the first quarter of 2026 and 115% from the prior-year quarter. For the first six months of 2026, revenue totaled $1.47 million, and second-quarter revenue alone represented about 83% of full-year 2025 revenue.
Gross profit was $766,000, for a gross margin of about 84%. The company recorded a net loss of $2.9 million, similar to a year earlier, and ended June 30, 2026 with $9.5 million in cash and cash equivalents, which it believes funds operations into the second half of 2027. Active commercial cancer center customers reached 21, with a total commercial funnel of 63 centers.
RenovoRx increased its 2026 revenue guidance to a range of $3.75–$4.25 million, implying approximately 241%–286% growth over 2025. The Phase III TIGeR-PaC trial of intra-arterial gemcitabine via RenovoCath has reached full enrollment, with completion expected in the first half of 2027 and topline data in the second half of 2027.
RenovoRx, Inc. is highlighting its oncology platform and clinical program through participation in a JonesTrading key opinion leader webinar on August 13, 2026, focused on pancreatic cancer and the company’s Trans-Arterial Micro-Perfusion (TAMP™) platform and RenovoCath® device.
The company reports that its first full year of commercial efforts in 2025 generated approximately $1.1 million in RenovoCath sales and a record $563,000 of sales in the first quarter of 2026. RenovoRx is evaluating intra-arterial gemcitabine delivered via RenovoCath in the ongoing Phase III TIGeR-PaC trial and states it anticipates full enrollment in the very near term and final data readout in mid to late 2027. The IAG combination product candidate remains investigational and not approved for commercial sale, while RenovoCath with gemcitabine has Orphan Drug Designation, which would provide seven years of market exclusivity upon potential FDA new drug application approval.
RenovoRx, Inc. reported that Nasdaq has granted it a second 180-day period, until December 28, 2026, to regain compliance with the exchange’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
To regain compliance during this second period, the company’s common stock must close at or above $1.00 per share for at least 10 consecutive business days, after which Nasdaq would issue written confirmation. If RenovoRx does not meet this standard by the new deadline, Nasdaq will notify the company that its common stock will be delisted, though RenovoRx would then have the opportunity to appeal the determination to a Nasdaq Hearings Panel.
RenovoRx, Inc. held its 2026 annual meeting of stockholders, with a quorum of about 22,825,465 shares present out of 45,052,706 shares entitled to vote as of May 11, 2026. Stockholders elected all seven director nominees to one-year terms, each receiving over 12.8 million votes.
Stockholders also approved an amendment to the Amended and Restated 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares of common stock, equal to 4.4% of total issued and outstanding shares, to the shares reserved for issuance under the plan (9,666,218 votes for, 3,565,088 against).
In addition, stockholders ratified the appointment of Frank, Rimerman + Co. LLP as independent registered public accounting firm for the year ending December 31, 2026, with 21,938,316 votes for, 477,181 against, and 409,966 abstentions.
RenovoRx, Inc. director Una S. Ryan, through The Una S. Ryan Revocable Trust, reported several "other" transactions in RenovoRx common stock classified as restructuring events rather than open-market trades. The filing shows a total of 97,165 shares involved in these non-derivative restructurings, all held indirectly by the trust after the reported changes.
Footnotes explain that the activity reflects distributions of RenovoRx shares from Astria Fund and Golden Seeds Venture Fund GP, entities where Ryan is a non-managing member. These entries reorganize how her indirect holdings are structured, with no reported open-market buying or selling.
RenovoRx, Inc. Chief Financial Officer Mark Voll reported an open-market purchase of 25,000 shares of Common Stock at $0.7876 per share on May 19, 2026. Following this purchase, he directly holds 142,380 shares and indirectly holds 97,200 shares through the Voll Family Trust.
A prior grant of 58,953 restricted stock units (RSUs) for his future CFO service remains partly unvested. As of April 30, 2026, 8,823 RSUs had vested and 50,130 RSUs were still unvested.